EntryPoint Capital’s Mirum Pharmaceuticals MIRM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$603K Hold
5,150
0.15% 249
2026
Q1
$476K Hold
5,150
0.14% 272
2025
Q4
$407K Sell
5,150
-2,728
-35% -$196K 0.16% 240
2025
Q3
$578K Buy
7,878
+612
+8% +$38.9K 0.22% 122
2025
Q2
$370K Sell
7,266
-2,409
-25% -$107K 0.19% 197
2025
Q1
$436K Buy
+9,675
New +$456K 0.2% 152
2024
Q3
Sell
-9,758
Closed -$334K 1065
2024
Q2
$334K Buy
9,758
+8,090
+485% +$212K 0.16% 136
2024
Q1
$41.9K Sell
1,668
-99
-6% -$2.72K 0.04% 845
2023
Q4
$52.2K Buy
+1,767
New +$53.5K 0.05% 698

Other funds holding MIRM

EntryPoint Capital's MIRM Position: Q2 2026 in Review

EntryPoint Capital held its Mirum Pharmaceuticals (MIRM) position steady in Q2 2026 at 5,150 shares worth $603K. The position accounts for 0.15% of the portfolio, ranked #249.

EntryPoint Capital first reported a position in MIRM in Q4 2023 and has held it in 9 quarters since. 328 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • EntryPoint Capital held 5,150 shares of Mirum Pharmaceuticals worth $603K as of Q2 2026.
  • EntryPoint Capital left its Mirum Pharmaceuticals share count unchanged in Q2 2026.
  • Mirum Pharmaceuticals made up 0.15% of EntryPoint Capital's portfolio in Q2 2026, its #249 holding.
  • EntryPoint Capital first reported a position in Mirum Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • 328 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.